ErVimmune

ErVimmune is a biotechnology company developing new therapeutic vaccines. From its funding announcement.

€17M Series A (first close)Raised 8 months agoLyon, FranceBiotech & PharmaFrance
Visit website →

In their own words

What ErVimmune says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "biotechnology company developing new therapeutic vaccines". Source

Why now

Where ErVimmune is today

ErVimmune announced a Series A round of €17M on 21 January 2026.

Latest round
Series A
Amount
€17M
Announced
21 January 2026
Headquarters
Lyon, France
Sector
Biotech & Pharma
Investors
Not stated
Also participating
Not stated
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

36
Established
0 funding signals in the last 90 days
Funding recency
9/40
announced within the last year
Round scale
12/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 21 January 2026
    €17M Series A
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Repeatable go-to-market build
  • First senior commercial hires

Opportunities this could create

  • Clinical operations
  • Regulatory affairs
  • CMC and manufacturing
  • Quality systems
  • Medical affairs

Based on the Biotech & Pharma sector and a Series A round. Not a statement of fact.

Early momentum1 connected signal
  • 21 January 2026€17M Series A announced

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What ErVimmune is open to

Not yet specified

ErVimmune has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with ErVimmune

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at ErVimmune?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: what the round is for, in your words, the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector